Skip to main content

Drug Interactions between aprocitentan and phenobarbital

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

PHENobarbital aprocitentan

Applies to: phenobarbital and aprocitentan

MONITOR: Coadministration with inducers of uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase or UGT) enzymes may decrease the systemic exposure and effects of aprocitentan, which is primarily metabolized by UGT1A1 and UGT2B7. Some UGT inducers are associated with similar adverse effects to those of aprocitentan, such as hepatotoxicity (e.g., alcohol, carbamazepine, efavirenz, fosphenytoin, phenytoin, rifampin). It is unclear if the use of aprocitentan with these substances could increase the risk of similar adverse effects. Clinical data examining aprocitentan with inducers of UGT are not available.

MANAGEMENT: Caution and clinical monitoring for reduced efficacy may be advised if aprocitentan is used with a UGT inducer. If the UGT inducer also shares a similar adverse effect profile with aprocitentan, like hepatotoxicity, additional monitoring for the adverse effect in question may also be recommended. Additional monitoring may also be beneficial if a UGT inducer is added to or withdrawn from the patient's regimen during aprocitentan therapy.

References (1)
  1. (2024) "Product Information. Tryvio (aprocitentan)." Idorsia Pharmaceuticals US Inc.

Drug and food interactions

Major

PHENobarbital food

Applies to: phenobarbital

GENERALLY AVOID: Concurrent acute use of barbiturates and ethanol may result in additive CNS effects, including impaired coordination, sedation, and death. Tolerance of these agents may occur with chronic use. The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.

MANAGEMENT: The combination of ethanol and barbiturates should be avoided.

References (5)
  1. Gupta RC, Kofoed J (1966) "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J, 94, p. 863-5
  2. Misra PS, Lefevre A, Ishii H, Rubin E, Lieber CS (1971) "Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats." Am J Med, 51, p. 346-51
  3. Saario I, Linnoila M (1976) "Effect of subacute treatment with hypnotics, alone or in combination with alcohol, on psychomotor skills related to driving." Acta Pharmacol Toxicol (Copenh), 38, p. 382-92
  4. Stead AH, Moffat AC (1983) "Quantification of the interaction between barbiturates and alcohol and interpretation of fatal blood concentrations." Hum Toxicol, 2, p. 5-14
  5. Seixas FA (1979) "Drug/alcohol interactions: avert potential dangers." Geriatrics, 34, p. 89-102

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer